FDA: Draft Guidance on Responding to Form 483 Observations

The US Food and Drug Administration (FDA) has issued a draft guidance on responding to Form FDA-483 observations following drug CGMP inspections. The document provides recommendations on how manufacturers should structure their responses and what information they should include.

Although submitting a written response is voluntary, it may be a key factor when FDA evaluates whether further regulatory action is warranted. The agency therefore recommends submitting responses within 15 business days after issuance of the FDA-483.

The draft guidance specifies several minimum elements that should be included in a response. These include:

• the identity of the establishment, including name, address and FEI number (FDA establishment Identifier)
• a copy of the issued FDA-483
• the identity of the response preparer and, if applicable, their relationship to the establishment
• the identity of the signatory, ideally from executive management with authority to allocate resources
• letters of authorization if consultants or external counsel are involved
• investigation plans and reports related to the observations
• an executive summary of remediation activities

In addition, the response should provide a detailed discussion of each observation, including:

• a patient- and product-focused risk assessment
• an investigation report describing scope, affected products and batches, root causes and systemic issues
• the CAPA plan, including completed actions and planned effectiveness checks
• supporting attachments, such as documents, data, images or diagrams.

The guidance also recommends organizing observations by topic or quality system and presenting the information in a clear and structured manner. The aim is to support effective communication with FDA and systematic remediation of inspection findings.

FDA: Responding to FDA Form 483 Observations at the Conclusion of a Drug CGMP Inspection